Supplemental material
Open access
3,913
Views
2
CrossRef citations to date
0
Altmetric
Report
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice
Jerome Eglia Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerlandhttps://orcid.org/0000-0002-0781-0773View further author information
, Stefan Heilera Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Felix Webera Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Guido Steinera Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Timo Schwandta Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Katharine Bray-Frencha Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Christian Kleinb Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, SwitzerlandView further author information
, Sebastian Fennc Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, GermanyView further author information
, Gregor P. Lotzc Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germanyhttps://orcid.org/0000-0002-0231-5503View further author information
, Eugenia Opolka-Hoffmannc Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, GermanyView further author information
, Thomas E. Kraftc Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germanyhttps://orcid.org/0000-0002-5528-3197View further author information
, Laetitia Petersena Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Rebecca Mosera Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Jonathan DeGeera Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Michel Siegela Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Daniela Finked Department of Biomedicine and University Children’s Hospital of Basel, University of Basel, Basel, Switzerlandhttps://orcid.org/0000-0003-4453-5958View further author information
, Juliana Bessaa Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandCorrespondence[email protected]
https://orcid.org/0000-0001-6730-3792View further author information
& https://orcid.org/0000-0001-6730-3792View further author information
Antonio Iglesiasa Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
show all
Article: 2143009
|
Received 12 Jul 2022, Accepted 28 Oct 2022, Published online: 17 Nov 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.